Abstract | BACKGROUND: METHODS/DESIGN: This is a randomized, double-blind, placebo-controlled, three-period crossover trial for a single subject. A total of 12 subjects will be recruited in this trial. The trial is divided into three cycles, and one cycle has two treatment periods. Ginkgo biloba pills and placebo will be randomized during the treatment period. The test period will last for 58 weeks and subjects will take 48 weeks. Subjects will be selected by the researcher strictly in accordance with the inclusion and exclusion criteria. DISCUSSION: Ginkgo biloba preparations are widely used in cardiovascular diseases both at home and abroad due to their definite curative effect, few side effects, various dosage forms, and convenient and safe use. Diabetes mellitus is a high-risk factor for the occurrence of cardiovascular disease. Therefore, it is of great significance to control the impaired glucose regulation and slow down the development of diabetes and reduce the incidence and mortality of cardiovascular diseases. This trial is registered with ClinicalTrials.gov (ID: NCT03483779).
|
Authors | Mingyue Sun, Lulu Chai, Fang Lu, Yang Zhao, Qingna Li, Boya Cui, Rui Gao, Yue Liu |
Journal | Evidence-based complementary and alternative medicine : eCAM
(Evid Based Complement Alternat Med)
Vol. 2018
Pg. 7571629
( 2018)
ISSN: 1741-427X [Print] United States |
PMID | 30405743
(Publication Type: Journal Article)
|